Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis

- Foong, Yi Chao, Merlo, Daniel, Darby, David, Dobay, Pamela, van Beek, Johan, Hyde, Robert, Simpson-Yap, Steve, Butzkueven, Helmut, van Der Walt, Anneke, Gresle, Melissa, Zhu, Chao, Buzzard, Katherine, Lechner-Scott, Jeannette, Barnett, Michael, Taylor, Bruce V., Kalincik, Tomas, Kilpatrick, Trevor

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

- Lal, Anoushka P., Foong, Yi Chao, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas‑Robledo, Simón, Moghadasi, Abdorreza Naser, Sanfilippo, Paul G., Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Spelman, Tim, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, Rath, Louise, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, Levitz, David, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, Van der Walt, Anneke, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas

CLADIN- CLADribine and INnate immune response in multiple sclerosis – A phase IV prospective study

- Monif, Mastura, Sequeira, Richard P., Maltby, Vicki E., Nguyen, Ai-Lan, Wesselingh, Robb, Seery, Nabil, Nesbitt, Cassie, Baker, Josephine, Dwyer, Chris, Taylor, Lisa, Rath, Louise, Van der Walt, Anneke, Muscat, Andrea, Marriott, Mark, Kalincik, Tomas, Lechner-Scott, Jeannette, O'Brien, Terence J., Butzkueven, Helmut, Stuckey, Sian, Sanfilippo, Paul G., Minh, Viet, Loftus, Naomi, Voo, Veronica, Fazzolari, Katherine, Moss, Melinda

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

- Foong, Yi Chao, Merlo, Daniel, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Kubala Havrdova, Eva, Weinstock-Guttman, Bianca, Lechner Scott, Jeanette, Boz, Cavit, Sa, Maria, Gresle, Melissa, Butzkueven, H, van der Walt, A, Zhu, C, MSBASE study group,, Buzzard, Katherine, Zhong, Michael, Yeh, Wei Zhen, Jokubaitis, Vilija, Monif, Mastura, Skibina, Olga, Ozakbas, Serkan

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

- Yeh, Wei Z., Van Der Walt, Anneke, Ozakbas, Serkan, Buzzard, Katherine, Habek, Mario, John, Nevin A., Prat, Alexandre, Girard, Marc, Duquette, Pierre, Baghbanian, Seyed Mohammad, Hodgkinson, Suzanne, Van Pesch, Vincent, Skibina, Olga G., Laureys, Guy, Willekens, B, Prevost, J, Foschi, M, De Gans, K, Horakova, D, Havrdova, EK, Karabudak, R, Patti, F, Mccombe, PA, Kalincik, Tomas, Maimone, D, Altintas, A, Ampapa, R, Spitaleri, D, Gerlach, OHH, Sa, MJ, Hughes, S, Gouider, R, Mrabet, S, Macdonell, RA, Alroughani, Raed, Turkoglu, R, Cartechini, E, Al-Asmi, A, Soysal, A, Oh, J, Muros-Le Rouzic, E, Guye, S, Pasquarelli, N, Butzkueven, H, Jokubaitis, VG, Kermode, Allan G., MSBase Study Group,, Fabis-Pedrini, Marzena J., Carroll, William M., Lechner-Scott, Jeannette, Boz, Cavit

Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study

- Kreiter, Daniel, Kalincik, Tomas, Lechner-Scott, Jeannette, Ozakbas, Serkan, Gerlach, Ozakbas, Turkoglu, R., Soysal, A., Boz, C., Al-Asmi, A., Alkhaboori, J., Amato, M. P., Onofrj, M., Hupperts, Raymond, Lugaresi, A., Besora, S, Sanchez-Menoyo, JL, Lapointe, E, Grand’Maison, F, Grammond, P, Butzkueven, H, Van der Walt, A, Taylor, BV, McCombe, PA, Patti, Francesco, Garber, JY, Skibina, OG, Buzzard, KA, John, NA, Shaw, C, Barnett, MH, Spitaleri, Daniele, Foschi, Matteo, Surcinelli, Andrea, Maimone, Davide, Yamout, Bassem, Khoury, Samia J.

Longitudinal epidemiology of multiple sclerosis over 60 years in Newcastle, Australia: 1961 to 2021

- Simpson-Yap, Steve, Maltby, Vicki E., Lechner-Scott, Jeannette, Hall, Stacey, Ward, Sophia, Lea, Rodney, Boggild, Mike, Kalincik, Tomas, Shaw, Cameron, Taylor, Bruce, van der Walt, Anneke

Oral corticosteroid dosage and tapeduration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

- Trewin, Benjamin P., Dale, Russell C., van der Walt, Anneke, Lechner-Scott, Jeanette, Butzkueven, Helmut, Broadley, Simon A., Barnett, Michael H., Reddel, Stephen W., Brilot, Fabienne, Kalincik, Tomas, Ramanathan, Sudarshini, Qiu, Jessica, Chu, Melissa, Jeyakumar, Niroshan, Dela Cruz, Fionna, Andersen, Jane, Siriratnam, Pakeeran, Ma, Kit Kwan M., Hardy, Todd A.

Patient-determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis

- Foong, Yi Chao, Merlo, Daniel, Darby, David, Dobay, Pamela, van Beek, Johan, Hyde, Robert, Butzkueven, Helmut, van der Walt, Anneke, Gresle, Melissa, Zhu, Chao, Buzzard, Katherine, Lechner-Scott, Jeannette, Barnett, Michael, Taylor, Bruce, Kalincik, Tomas, Kilpatrick, Trevor

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele L. A., Pesch, Vincent Van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, Abdullah, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, MSBase Study Group,, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

- Kalincik, Tomas, Sharmin, Sifat, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trnený, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, Roos, Izanne, McCombe, Pamela, Skibina, O, Lechner-Scott, Jeanette, Willekens, B, Cartechini, E, Ozakbas, S, Alroughani, R, Kuhle, J, Patti, F, Duquette, P, Freedman, Mark S., Lugaresi, A, Khoury, SJ, Slee, M, Turkoglu, R, Hodgkinson, S, John, N, Maimone, D, Sa, MJ, van Pesch, V, Gerlach, O, Atkins, Harold, Laureys, G, Van Hijfte, L, Karabudak, R, Spitaleri, D, Csepany, T, Gouider, R, Castillo-Triviño, T, Taylor, B, Sharrack, B, Snowden, JA, Burman, Joachim, MSBase Study Group Collaborators,, MSBase Study Group Authors,, Mrabet, S, Garber, J, Sanchez-Menoyo, JL, Aguera-Morales, E, Blanco, Y, Al-Asmi, A, Weinstock-Guttman, B, Fragoso, Y, Massey, Jennifer, de Gans, K, Kermode, A, MSBase Study Group,, Sutton, Ian, Withers, Barbara, Macdonell, Richard

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele L. A., van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, A, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation

- Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens

Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022

- Simpson-Yap, Steve, Maddox, Duncan, Reece, Jeanette, Lechner-Scott, Jeannette, Shaw, Cameron, Taylor, Bruce, Kalincik, Tomas, van der Walt, Anneke, Boggild, Mike

Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity

- Jokubaitis, Vilija G., Campagna, Maria Pia, Lea, Rodney, Kilpatrick, Trevor J., Kalincik, Tomas, De Jager, Philip L., Beecham, Ashley, McCauley, Jacob L., Taylor, Bruce V., Vucic, Steve, Laverick, Louise, Vodehnalova, Karolina, Ibrahim, Omar, García-Sanchéz, Maria-Isabel, Alcina, A, van der Walt, A, Havrdova, EK, Izquierdo, G, Patsopoulos, N, Horakova, D, Butzkueven, H, Stankovich, Jim, Kleinova, Pavlina, Matesanz, Fuencisla, Hui, Daniel, Eichau, Sara, Slee, Mark, Lechner-Scott, Jeannette

Prediction of relapse activity when switching to cladribine for multiple sclerosis

- Zhong, Michael, van der Walt, Anneke, Butler, Ernest, Prevost, Julie, Girard, Marc, Oh, Jiwon, Butzkueven, Helmut, Jokubaitis, Vilija, Monif, Mastura, Hodgkinson, Suzanne, Eichau, Sara, Kalincik, Tomas, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Van Pesch, Vincent

Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity

- Spelman, Tim, Horakova, Dana, Csepany, Tunde, Boz, Cavit, Lechner-Scott, Jeannette, Granella, Franco, Grand'Maison, Francois, van der Walt, Anneke, Zhu, Chao, Butzkueven, Helmut, Ozakbas, Serkan, Alroughani, Raed, Onofrj, Marco, Kalincik, Tomas, Prat, Alexandre, Terzi, Murat, Grammond, Pierre, Patti, Francesco

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

- Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph

Multiple Sclerosis Relapses Following Cessation of Fingolimod

- Malpas, Charles B., Roos, Izanne, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Kalincik, Tomas, MSBase Study Group,, Sharmin, Sifat, Buzzard, Katherine, Skibina, Olga, Butzkueven, Helmut, Kappos, Ludwig, Patti, Francesco, Alroughani, Raed, Horakova, Dana

Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

- Kalincik, Tomas, Kister, Ilya, Ozakbas, Serkan, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Bacon, Tamar E., Terzi, Murat, Boz, C, Grand'Maison, F, Bergamaschi, R, Gerlach, O, Sa, MJ, Kappos, L, Cartechini, E, Lechner-Scott, Jeannette, van Pesch, V, Malpas, Charles B., Shaygannejad, V, Granella, F, Spitaleri, D, Iuliano, G, Maimone, D, Prevost, J, Soysal, A, Turkoglu, R, Ampapa, R, Butzkueven, H, Sharmin, Sifat, Cutter, G, for MSBase Study Group,, Horakova, Dana, Kubala-Havrdova, Eva, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara